Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Clinical Trial to Confirm Efficacy and Evaluate Safety of Twice-daily Delgocitinib Cream 20 mg/g Compared With Cream Vehicle for a 16-week Treatment Period in Adult Subjects With Moderate to Severe Chronic Hand Eczema (DELTA 2)

NCT04872101 is registered in ClinicalTrials.gov with LEO Pharma as lead sponsor.

NCT NCT04872101
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04872101 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Clinical Trial to Confirm Efficacy and Evaluate Safety of Twice-daily Delgocitinib Cream 20 mg/g Compared With Cream Vehicle for a 16-week Treatment Period in Adult Subjects With Moderate to Severe Chronic Hand Eczema (DELTA 2)
Lead sponsor
LEO Pharma
Phase
Phase 3
Overall status
Completed
Start date
May 25, 2021
Completion date
January 6, 2023
Enrollment
473 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hand eczema